Laekna, Inc. Advances LAE123 for Severe Diseases
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At ...
The Pharma Letter1d
Amgen’s MariTide falls short of analyst expectations in obesity
The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...
Daily4d
Eli Lilly Collaborates with Laekna to Develop Obesity Drug Targeting Muscle Preservation and Weight Loss
Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...
The Pharma Letter6d
Lilly and Laekna team up on novel obesity drugs
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
BioSpace6d
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...